ATLASATLAS fair value
ATLAS has no fair value for this stock today.
TransCode Therapeutics (RNAZ)
TransCode Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$1.71▼ -3.64%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on TransCode Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On TransCode Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives TransCode Therapeutics a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $1.46 and $1.92; in 9 out of 10, between $1.14 and $2.46. Estimated annual volatility is 70%.
Price, last 12 months (weekly close)
Key numbers
- 52-week high
- $13.21
- 52-week low
- $1.52
- Revenue (12 months)
- $0.0M
- Return on equity
- -59.3%
- Free cash flow (12 months)
- $-13.8M
- Beta
- 1.17
What this means
ATLAS does not publish a fair value for RNAZ right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks RNAZ has traded between $1.52 and $13.21. Today it is 87.1% below that high and 13% above its low.
Its beta is 1.17: it tends to move more than the market, both up and down.
About the company
TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies and immuno-oncology programs for high-risk and advanced cancers.
Want to see everything about TransCode Therapeutics?
Get started →Plans from €3.99 a month.
Frequently asked questions
What does TransCode Therapeutics do?
TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies and immuno-oncology programs for high-risk and advanced cancers.
What is the chance RNAZ goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, RNAZ ends the month between $1.46 and $1.92.
How volatile is RNAZ?
ATLAS estimates annual volatility at 70%. In a typical month, half of the outcomes end between $1.46 and $1.92.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer